elililly
-
New Trial Data Is Strongest Yet for Any Experimental Alzheimer’s Drug
New clinical trial data released by Eli Lilly on Wednesday has provided the most promising results of any potential Alzheimer’s disease treatment yet. In a randomised, double-blinded, controlled phase III trial, the experimental drug donanemab significantly slowed cognitive decline in patients compared to placebo, with nearly half of those on the drug experiencing no decline…
-
The Biggest Medical Breakthroughs of 2022
Cancer-fighting viruses, gene therapies, and a new class of hair-loss drugs are some of the year’s most exciting medical advances.
-
How Much Did Twitter’s Verification Chaos Cost Insulin Maker Eli Lilly and Twitter Itself?
As much as last week’s $US8 ($11) Twitter verification chaos warped many public faces into gross parodies of their sterilized brands, one pharma company that has long hiked the price of a life-saving drug was caught in the crossfire and may have lost millions because of one fake post. New reports reveal just how much…
